Five-strain meningitis vaccine was 92% effective in a Niger outbreak, study finds
A case-control study by MSF's Epicentre and WHO put NmCV-5's adjusted effectiveness at 92% against meningococcal meningitis after 2024 campaigns in Niger — on a small sample of 17 confirmed cases.
| Group | Value (%) |
|---|---|
| Crude, all serogroups | 88 (62 to 96) |
| Crude, serogroup C | 86 (50 to 96) |
| Adjusted, all serogroups | 92 (72 to 98) |
| Adjusted, serogroup C | 91 (63 to 98) |
A five-strain meningococcal vaccine used in Niger's 2024 outbreak response was highly protective in the first real-world test of its field effectiveness, with an adjusted estimate of 92% against meningococcal meningitis (95% confidence interval 72–98) [s1]. The finding, from a matched case-control study by Médecins Sans Frontières' research arm Epicentre and WHO, is encouraging but rests on a small sample — 17 laboratory-confirmed cases — so the true figure could plausibly sit anywhere across a wide range [s1].
The vaccine, NmCV-5, is a pentavalent conjugate that targets meningococcal serogroups A, C, W, Y and X, and was prequalified by WHO in 2023 [s1]. It matters because of a gap left by an earlier success. In the African meningitis belt, which stretches from Senegal to Ethiopia and is prone to recurrent epidemics, serogroup A accounted for 80–85% of meningitis epidemics before a meningococcal A conjugate vaccine was rolled out from 2010 [s2]. That campaign all but ended serogroup A epidemics, but outbreaks driven by serogroups C, W and X persisted — the problem a five-strain vaccine is meant to close [s1]. In 2023 the first pentavalent meningococcal conjugate vaccine reached use [s2], and Niger deployed NmCV-5 in reactive campaigns during 2024 [s1].
What the study measured
Researchers ran a matched case-control study across six health districts in Niger — in Niamey IV and Magaria — enrolling patients between May 2024 and July 2025 [s1]. Cases were people aged 1 to 19 with PCR-confirmed meningococcal meningitis who lived in a vaccination-campaign area and whose symptoms began at least 10 days after the campaign; each case was matched to four community controls of the same age, sex and residence [s1]. Vaccination was confirmed by a patient-held card where available, and otherwise self-reported [s1].
In all, 17 confirmed cases — 14 caused by serogroup C and three by serogroup W — and 68 matched controls were enrolled [s1]. Seven of the cases (41%) and 58 of the controls (86%) reported having received NmCV-5 [s1]. Crude vaccine effectiveness against all meningococcal meningitis was 88% (95% CI 62–96), and 86% (50–96) against serogroup C specifically [s1]. After adjustment for household crowding and recent respiratory infection, effectiveness rose to 92% (72–98) overall and 91% (63–98) for serogroup C, and the authors report that sensitivity analyses held up under extreme assumptions about the unconfirmed vaccination statuses [s1].
The limits, stated plainly
The headline number is high, but the study is small and its authors say so. With only 17 cases, the confidence intervals are wide, and the lower bound of the crude serogroup C estimate falls to 50% — so the data are consistent with effectiveness that is very high or merely moderate [s1]. Vaccination status leaned on self-report for most participants, which can bias effectiveness estimates in either direction, and no cases from other targeted serogroups were captured, so the result speaks to the C and W strains actually circulating rather than to all five the vaccine covers [s1]. The authors call for further work on how well NmCV-5 blocks carriage of the bacteria and prevents invasive disease across all its target serogroups [s1].
Even hedged, the direction is the one public-health agencies were hoping for. Meningococcal meningitis is usually fatal without treatment and can kill within hours, and the belt's reactive-campaign model — vaccinating in response to a detected outbreak — depends on a vaccine that works fast and broadly enough to blunt an epidemic already under way [s2]. A field estimate near 90% against the strains that caused this outbreak is the first real-world signal that NmCV-5 can do that job; confirming it will take larger studies across more of the serogroups it was built to cover [s1].
This article is informational and is not medical advice.
Sources
- [s1] Cooper LV, et al., "Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study," Vaccine, 2026. https://doi.org/10.1016/j.vaccine.2026.128997
- [s2] World Health Organization, "Meningococcal meningitis" fact sheet. https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis
Sources
- Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study — Vaccine (Cooper LV, et al.) , August 12, 2026
- Meningococcal meningitis (fact sheet) — World Health Organization
More on
Meningococcal cases tracked Umrah as pilgrim vaccination compliance fell to 54%
WHO recorded serogroup W135 disease in pilgrims returning from Saudi Arabia in early 2025. A modelling study estimates high vaccination coverage would cut expected cases by more than 80%.
Flu vaccine still cut hospitalisations despite the subclade K mismatch
WHO flagged a drifted A(H3N2) subclade K in December; the first 2025-2026 effectiveness data, from 1.4 million US veterans, put overall protection near 22% and protection against hospitalisation near 32%.
Why Congo's Bundibugyo Ebola outbreak has no vaccine, when other Ebola does
The vaccines and antibody drugs that cut Ebola's death rate work against the Zaire species. None is approved for the Bundibugyo virus now driving the largest Ebola outbreak in Congo's history.
Yellow fever spreads beyond its usual range in 2026, WHO reports
A WHO global update logged 79 human infections in the Americas and 16 confirmed cases in Africa by late May, with the virus surfacing in areas long considered free of it.